Are we ready for an MRD-driven approach in multiple myeloma?

The MIDAS study investigates an MRD-driven approach for newly diagnosed multiple myeloma (NDMM), aiming to individualize treatment based on response. A prolonged, carfilzomib-based quadruplet induction achieved high post-induction MRD negativity rates (63%). MRD negativity is a strong predictor of long-term remission and survival. The study suggests this approach could establish MRD-driven treatment as the new gold standard.